Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Supernus (SUPN)

Supernus completes merger; SUPN stock to be delisted from Nasdaq

Neutral Impact 5 of 5 m&a

Supernus Pharmaceuticals completed a merger on November 2, 2026, and asked Nasdaq to suspend trading in its common stock before the market opened that day. The company will be removed from Nasdaq and will stop being a publicly listed stock, so shares will no longer trade on any national securities exchange.

Key points

  • Merger consummated November 2, 2026; trading in Supernus common stock suspended before market open that day
  • Company requested Nasdaq file a Form 25 to delist the stock and deregister it under Section 12(b)
  • After Form 25 takes effect, company intends to file Form 15 to deregister under Section 12(g) and suspend SEC reporting obligations

The filing

CompanySupernus (SUPN)
Form8-K, current report
Filed with the SECNov 2, 2026, 10:50 AM ET
Accession number0001104659-26-121103

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.